

Curriculum Vitae
January 27, 2015

PERSONAL DATA

Erik T. Goluboff, MD FACS
Board Certified Urologist
Urologic Surgery
Urologic Oncology

Current Positions:
Attending Physician
Urologic Oncology/Urologic Surgery
Department of Urology
Mount Sinai Beth Israel Medical Center
10 Union Square East, Suite 3A
New York, NY 10003
(212) 844-8941
fax (212) 844-8901

Professor of Urology
Icahn School of Medicine at Mount Sinai

DOB: 9/21/64
Place of Birth: Brooklyn, NY
Citizenship: U.S.

EDUCATION

Columbia College, Columbia University, New York, NY; BA, 1986 (Biology).
Johns Hopkins University School of Medicine, Baltimore, MD; MD, 1990.
Executive MBA Program, Stern School of Business, New York University, New
York, NY, January, 2015 (Financial Instruments, Corporate Finance, Management).

POSTDOCTORAL TRAINING

Surgical Intern, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD;
7/1/90-6/30/91

Surgical Resident, Department of Surgery, Columbia-Presbyterian Medical Center,
New York, NY; 7/1/91-6/30/92

Urology Resident, Department of Urology, Columbia-Presbyterian Medical Center,
New York, NY; 7/1/92-6/30/96

Chief Resident, Department of Urology, Columbia-Presbyterian Medical Center, New York, NY; 7/1/95-6/30/96

Fellow, Urologic Oncology, Department of Urology, Columbia-Presbyterian Medical Center, New York, NY; 7/1/96-6/30/97.

LICENSURE/CERTIFICATION

New York State License #186581, 1991-.

Certified by the American Board of Urology, 1999; recertified, 2007.

MILITARY SERVICE: none.

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

Member, Southwest Oncology Group
 Member, Genitourinary Committee, Southwest Oncology Group
 Fellow, American College of Surgeons
 American Urological Association
 Society of Urologic Oncology
 New York Section, American Urological Association
 American Society of Clinical Oncology
 American Medical Association

ACADEMIC APPOINTMENTS

Assistant Professor, Department of Urology, College of Physicians and Surgeons, Columbia University, 9/1/96-6/30/02.

Associate Professor of Clinical Urology, Department of Urology, College of Physicians and Surgeons, Columbia University, 7/1/02-6/30/07.

Professor of Clinical Urology, Department of Urology, College of Physicians and Surgeons, Columbia University, 7/1/07-6/30/11.

Professor of Clinical Urology, Albert Einstein College of Medicine, Yeshiva University, 7/1/11-6/30/14.

Professor of Urology, Icahn School of Medicine at Mount Sinai, 1/1/14-.

HOSPITAL APPOINTMENTS

Assistant Attending, Department of Urology, Columbia-Presbyterian Medical Center, 9/1/96-6/30/02.

Director of Urology, Allen Pavilion, Columbia-Presbyterian Medical Center, 10/23/98-6/30/11.

Director of Residents' Clinic, Columbia-Presbyterian Medical Center, 10/23/98-6/30/11.

Associate Attending, New York Presbyterian Hospital, Presbyterian Campus, 7/1/02-6/30/07.

Attending, New York Presbyterian Hospital, Presbyterian Campus, 7/1/07-6/30/11.

Attending, Beth Israel Medical Center, 7/1/11-.

HONORS

Alpha Omega Alpha, Johns Hopkins School of Medicine, 1990.

First Prize winner, Ambrose Essay Contest, American Urological Association, Washington, DC, 1992, for: Goluboff E and Olsson CA: *Urologists on a tightrope: Coping with a changing economy.*

First prize winner, Best Poster, American Fertility Society, San Antonio, 1994, for: Goluboff E, Mertz JR, Tres LL, and Kierszenbaum AL: *Biochemical, immunocytochemical, and molecular characteristics of human sperm and testis galactosyl receptor.*

First Prize winner, Laboratory Investigation-Formal Year, Valentine Essay Contest, New York Academy of Medicine, New York, 1994, for: *Biochemical, immunocytochemical, and molecular characteristics of human sperm and testis galactosyl receptor.*

Columbia-Presbyterian Housestaff Mini-Grant Award, 1995-1996.

Pfizer Scholar in Urology, 1996.

American Society of Clinical Oncology Young Investigator Award, 1996.

New York Academy of Medicine Valentine Fellowship Award, 1996.

Second Honorable Mention, Clinical Investigations, Valentine Essay Contest, New York Academy of Medicine, New York, 1996, for: *Semen analyses in 1283 men from the United States over a 25-year period: No decline in quality.*

Pfizer Scholar in Urology, 1997.

Teacher of the Year, Department of Urology, College of Physicians and Surgeons, Columbia University, 2003.

Castle Connolly Top Doctors New York Metro Area 2008-.

Consumers' Research Council of America, America's Top Urologists, 2009-

Patient's Choice Award 2009, 2010, 2011

Compassionate Doctor Award 2011

Consumers' Research Council of America, America's Top Surgeons, 2012-

Teacher of the Year, Department of Urology, Beth Israel Medical Center, 2012

OTHER HONORS

National Merit Scholarship Finalist, 1982.

Regent's Scholarship, 1982.

Phi Beta Kappa, Magna Cum Laude, Columbia University, 1986.

Richard Goodrich Jackson Memorial Prize, Columbia University, 1986.

FELLOWSHIP AND GRANT SUPPORT

1995; "Pre-Treatment Prostate-Specific Antigen Doubling Times: Utility in Patients Before Radical Prostatectomy"; Principal Investigator; \$2500; Columbia-Presbyterian Housestaff Mini-Grant Award.

1996; "Apoptosis-inducing Gene Therapy for Hormone-Refractory Prostate Cancer"; Young Investigator Award; \$30,000; American Society of Clinical Oncology.

1997; "Apoptosis-inducing Gene Therapy for Hormone-Refractory Prostate Cancer"; Young Investigator Award; \$30,000; New York Academy of Medicine.

1997-98; "FGN-1 in the Treatment of a Human Prostate Cancer Nude Mouse Xenograft Model"; Principal Investigator; \$65,000; Cell Pathways, Inc.

1998-99; "FGN-1 in the treatment of prostate cancer"; Young Investigator Award; \$25,000; National Kidney Foundation of New York and New Jersey.

1998-99; "A randomized, double-blind, placebo-controlled study to determine the efficacy and safety of FGN-1 in patients with prostate cancer"; Principal Investigator; \$450,000; Cell Pathways, Inc.

1999; “An Open Label, Multi-Center, Extension Study to Determine the Efficacy and Safety of Prevatac (exisulind) in Patients with Prostate Cancer”; Principal Investigator; \$78,000; Cell Pathways, Inc.

1999; “A Randomized, Multi-Center, Phase III Trial Evaluating the Efficacy and Safety of BCI-Immune Activator Versus Adriamycin in BCG Refractory or Intolerant Patients with Carcinoma in situ with or without Resected Superficial Papillary Bladder Cancer”; Principal Investigator; \$42,000; Intracel, Inc.

2001-3; “A Multicenter, Phase IIb, Four Arm, Dose Finding, Randomized, Placebo-Controlled Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of 20mg, 40mg & 60mg Daily of GTx-006 in Men with High Grade Prostate Intraepithelial Neoplasia (PIN)”; Principal Investigator; \$240,000; GTx, Inc.

DEPARTMENTAL AND UNIVERSITY COMMITTEES

Resident Education Committee, Department of Urology, Columbia University, 1993-1995, and 1999-2011; 2005: wrote 35 lecture curriculum for resident weekly Campbell’s Review Conference.

Resident Selection Committee, Department of Urology, Columbia University, 1998-; Chair, 2006-2011.

Operating Room/Anaesthesia Committee, Allen Pavilion, Columbia-Presbyterian Medical Center, 1997-; Chair, 2001-2011.

**Compliance Leader, Department of Urology, Columbia University, 2001-4.
Executive Committee, Department of Urology, Columbia University, 2007-2011.
Compensation Committee, Department of Urology, Columbia University, 2007-2011.**

**Member, Faculty Council of College of Physicians and Surgeons, 2001-4, 2007-2011;
Member, Independent Evaluation Group, Faculty Practice Organization, Columbia University (Electronic Medical Record evaluation and selection).**

Member, Physician Champion Committee, Faculty Practice Organization, Columbia University (Electronic Medical Record implementation).

Member, Website Committee, Department of Urology, Columbia University, 2007-2011.

Alumni interviewer, Columbia College, Columbia University, 2008-.

Member, Institutional Review Board, Beth Israel Medical Center, 2011-.

Member, Resident Selection Committee, Department of Urology, Beth Israel Medical Center, 2011-.

Member, Quality Assurance Committee, 10 Silver, Beth Israel Medical Center, 2011-.

Member, Curriculum Committee, Department of Urology, Beth Israel Medical Center, 2011-.

TEACHING EXPERIENCE

Preceptor, Department of Internal Medicine, College of Physicians and Surgeons, Columbia University, 1998-2011.

Preceptor, Department of Family Medicine, College of Physicians and Surgeons, Columbia University, 1998-2011.

Faculty, “Exisulind in the Treatment of Advanced Prostate Cancer”, 8th International Prostate Cancer Update, Medical Education Cooperative, 1999.

Keynote Speaker, “Protecting Yourself Against Prostate Cancer”, Annual meeting of the combined Us Too prostate cancer support groups of the greater Chicago area, 1999. (videotape of this talk was later used as a training video for sales representatives for Cell Pathways, Inc.)

Faculty, “Exisulind in the Treatment of Advanced Prostate Cancer”, 9th International Prostate Cancer Update, Medical Education Cooperative, 2000.

Lecturer, Required Third Year Clerkship in Urology, College of Physicians and Surgeons, Columbia University, 2001-2011.

Preceptor, MD-PhD Program, College of Physicians and Surgeons, Columbia University, 2003.

Faculty, “Urology for Primary Care Practitioners”, College of Physicians and Surgeons, Columbia University, 2006-2007.

Preceptor, Department of Family Medicine, Beth Israel Medical Center, 2011-.

Lecturer, Department of Medicine Noon Conference, Beth Israel Medical Center, 9/22/11.

Speaker, “Radical Prostatectomy: Patient selection and outcomes”, Uro-Updates New York 2011, 10/17/11.

Speaker, “Partial Nephrectomy: Patient selection”, Uro-Updates New York 2011, 10/17/11.

Speaker, “Prostate Cancer: A Patient-Centered Approach”, Department of Urology Grand Rounds, Beth Israel Medical Center, 10/27/11.

Speaker, “Prostate Cancer: A Patient-Centered Approach”, Department of Family Medicine Grand Rounds, Beth Israel Medical Center, 11/3/11.

OTHER PROFESSIONAL ACTIVITIES

Consultant, *Journal of Urology*; 1996-2012.

Co-Series Editor, *Urology Board Review Manual*, published by Hospital Physician/Turner White Communications, Inc.; 1997.

Series Editor, *Urology Board Review Manual*, published by Hospital Physician/Turner White Communications, Inc.; 1998-2001.

Reviewer, *Urology*; 1998-.

Reviewer, *Urologic Oncology*, 1999-.

Consultant, *Pharmacoeconomics*, 2000-.

Expert Consultant, New York State Board for Professional Medical Conduct, 2001-.

Reviewer, *New England Journal of Medicine*, 2001.

Reviewer, Department of Defense, Prostate Cancer Initiative, 2001-.

Reviewer, *Cancer Detection and Prevention*, 2001.

Reviewer, *Drugs and Aging*, 2002.

Reviewer, *British Journal of Urology*, 2003-.

Medical Consultant, New York State Comptroller’s Medical Board, 2003-.

Reviewer, *Asian Journal of Andrology*, 2003-.

Reviewer, *Expert Opinion in Pharmacology*, 2003.

Member, Committee on Health Care Delivery Systems and Medicaid, Medical Society of the State of New York, 2004-2010.

Program Abstract Review Committee, American Urological Association, 2006-2013.

Editorial Board, *Minimally Invasive Surgery*, 2009-.

Editorial Board, *SRPJU*, 2011-.

Editorial Board, *World Journal of Clinical Urology*, 2011-.

Editorial Board, *Andrology Open Access Journal*, 2011-.

CERTIFICATIONS

Video Laser Ablation of the Prostate, S. Kaplan, MD, Columbia-Presbyterian Medical Center, New York, NY, 1993.

Lithotripsy, MFL 5000, S. Saada, MD, Victory Memorial Medical Center, Brooklyn, NY, 1994.

Microsurgery (including vasovasostomy, vasoepididymostomy, arterial, venous, and nerve anastomoses), Microsurgery Laboratory, Department of Orthopedics, Columbia-Presbyterian Medical Center, New York, NY, 1994.
 Basic and Advanced Laparoscopic Skills, IMET Training Course, 2004.
 Urologic Robotic Surgery, Newark Beth Israel Hospital, Newark, NJ, March 2007.
 Advanced Course in Robotic Prostatectomy, Sunnyvale, CA, 11/14-15/08.
 Leadership/Management Institute 2009, Columbia University Medical Center, January 9-10, February 6-7, 2009.

ORIGINAL, PEER REVIEWED PUBLICATIONS

Lopez R, Gouras P, Kjeldbye H, Sullivan B, Repucci V, and **Goluboff E**: *Transplanted RPE slows the retinal degeneration in the RCS rat*. Invest Ophth (1989) 145: 201-204.

Goluboff E, Chang DT, Kirsch AJ, and Fisch H: *Incidence of external spermatic veins in patients undergoing inguinal varicocelectomy*. Urology (1994) 44: 893-896.

Goluboff E and Olsson CA: *Urologists on a tightrope: Coping with a changing economy*. J Urol (1994) 151: 1-4.

Jarow J, **Goluboff ET**, Chang TSK, and Marshall FF: *Relationship between anti-sperm antibodies and testicular histologic changes in humans after vasectomy*. Urology (1994) 43: 521-524.

Goluboff E, Mertz J, Tres LL, and Kierszenbaum AL: *Biochemical, immunocytochemical, and molecular characteristics of human testis and sperm galactosyl receptor*. Surgical Forum, American College of Surgeons (1994) 45: 780-784.

Olsson CA and **Goluboff E**: *Detection and treatment of prostate cancer: The urologist's perspective*. J Urol (1994) 152: 1695-1699.

Goluboff E, McKiernan J, Todd G, Nowygrod R, and Olsson CA: *Reconstruction of urinary and gastrointestinal tracts in total pelvic exenteration: Experience at Columbia-Presbyterian Medical Center*. Urology (1994) 44: 666-670.

Goluboff E, Mertz JR, Tres LL, and Kierszenbaum AL: *Galactosyl receptor in human testis and sperm is antigenically related to the minor C-type (Ca²⁺-dependent) lectin variant of human rat and liver*. Molecular Reproduction and Development (1995) 40: 460-466.

***Goluboff E**, Chang DT, Olsson CA, and Kaplan SA: *Urodynamics and the etiology of post-prostatectomy urinary incontinence: The initial Columbia Experience*. J Urol (1995) 153: 1034-1037.

*Kaplan SA, **Goluboff E**, Olsson CA, Deverka PA, and Chmiel JJ: *Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.* Urology (1995) 45: 398-405.

Goluboff E, Stifelman M, and Fisch H: *Ejaculatory duct obstruction in the infertile male.* Urology (1995) 45: 925-931.

Fisch H, **Goluboff E**, Olsen JH, Feldshuh J, Broder SJ, and Barad D: *Semen analyses in 1283 men from the United States over a 25-year period: No decline in quality.* Fertility and Sterility (1996) 65: 1009-1014.

Fisch H and **Goluboff E**: *Geographic variations in sperm counts: A potential cause of bias in studies of semen quality.* Fertility and Sterility (1996) 65: 1044-1046.

Seaman EK, **Goluboff E**, Bar-Chama N, and Fisch H: *Accuracy of semen counting chambers as determined by the use of latex beads* Fertility and Sterility (1996) 66: 662-665.

Seaman EK, **Goluboff E**, Ross S, and Sawczuk IS: *Bone metastases and serum alkaline phosphatase levels in patients with metastatic renal cell carcinoma.* Urology (1996), 48: 692-695.

Ikeguchi E, **Goluboff E**, and Fisch H: *Worldwide variations in sperm counts.* Urology (1996), 48: 1017-1020.

***Goluboff E**, Heitjan DF, deVries GM, Katz AE, and Olsson CA: *Pre-treatment prostate-specific antigen doubling times: Utility in patients before radical prostatectomy.* J Urol (1997), 158: 1876-1879.

Fisch H, Andrews H, **Goluboff E**, Hendricks J, Olson J, and Olsson CA: *The relationship of sperm counts to birth rates: A population-based study.* J Urol (1997), 157: 840-843.

Dorai T, **Goluboff E**, Olsson CA, and Buttyan R: *Development of a hammerhead ribozyme against Bcl-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.* Anticancer Res (1997) 17: 3307-3312.

De La Taille A, Houlgatte A, Houdelette P, **Goluboff ET**, Berlizot P, and Ricordel I: *Influence of free to total PSA variability on the early diagnosis of prostate cancer: Comparative study of 3 immunoassays on 141 patients.* Br J Urol (1998) 82: 389-392.

***Goluboff E**, Saidi J, Mazer S, Bagiella E, Heitjan DF, Benson MC, and Olsson CA: *Urinary continence after radical prostatectomy: The Columbia experience.* J Urol (1998), 159: 1276-1280.

Emanuel ER, **Goluboff E**, and Fisch H: *MacLeod revisited: Sperm count distribution in 374 fertile men from 1971 to 1994*. Urology (1998), 51: 86-88.

Dorai T, Perlman H, Walsh K, Shabsigh A, **Goluboff ET**, Olsson CA, and Buttyan R: *A recombinant defective adenovirus agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2 expressing human prostate cancer cells*. Int J Cancer (1999), 82: 846-852.

McKiernan JM, **Goluboff ET**, Liberson GL, Golden R, and Fisch H: *Rising risk of developing testicular cancer by birth cohort in the United States from 1973-1995*. J Urol (1999) 162: 361-363.

Houlgatte A, De La Taille A, Fournier R, **Goluboff ET**, Camporio P, and Houdelette P: *Paternity in a patient with seminoma and carcinoma in situ in a solitary testis treated with partial orchidectomy*. BJU International (1999) 84: 374-375.

Shabsigh A, Danji N, Dagati V, Burchardt M, Rubin M, **Goluboff E**, Heitjan D, Kiss A, and Buttyan R: *Early effects of castration on the vascular system of the rat ventral prostate gland*. Endocrinology (1999) 140: 1920-1926.

Saidi JA, Chang DT, **Goluboff ET**, Bagiella E, Olsen G, and Fisch H: *Declining sperm counts in the United States? A critical review*. J Urol (1999) 161: 460-462.

***Goluboff ET**, Shabsigh A, Saidi J, Bagiella A, Heitjan D, Piazza G, Pamukcu R, Weinstein IB, Buttyan R, and Olsson CA: *Exisulind (Sulindac Sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis*. Urology (1999) 53: 440-445.

Saidi JA, Chang DT, **Goluboff ET**, Bagiella E, Olsen G, and Fisch H: *Declining sperm counts in the United States? A critical review*. J Urol (1999) 161: 460-462.

***Goluboff ET**: *Exisulind, a selective apoptotic antineoplastic drug*. Expert Opinion on Invest Drugs (2001) 10: 1875-1882.

***Goluboff ET**, Prager D, Rukstalis D, et al.: *Safety and Efficacy of Exisulind in the Treatment of Recurrent Prostate Cancer Following Radical Prostatectomy*. J Urol (2001) 166: 882-886.

Nejat RJ, Purohit R, **Goluboff ET**, Petrylak D, Rubin MA, and Benson MC: *Cure of undifferentiated small cell carcinoma of the urinary bladder with M-VAC chemotherapy*. Urologic Oncology (2001) 6: 53-55.

Fisch H, Kang YM, Johnson CW, and **Goluboff ET**: *Ejaculatory duct obstruction*. Curr Opin Urol (2002) 12: 509-515.

*Lam, JS, Desai M, Mansukhnai MM, Benson MC, and **Goluboff ET**: *Is Hispanic race an independent risk factor for pathologic stage in patients undergoing radical prostatectomy?*. J Urol (2003) 170: 2288-2291.

Salomon L, Anastasiadis A, Johnson C, McKiernan JM, **Goluboff ET**, Abbou CC, Olsson CA, and Benson MC: *Seminal vesicle involvement after radical prostatectomy: Predicting risk factors for progression*. Urology (2003) 62: 304-309.

*Lam JS, Benson MC, and **Goluboff ET**: *Comparison of the predictive accuracy of serum prostate-specific antigen levels and prostate-specific antigen density in the detection of prostate cancer in Hispanic-American and Caucasian men*. J Urol (2003) 170: 451-456.

Johnson CW, McKiernan JM, Anastasiadis AG, Salomon L, Easton S, **Goluboff ET**, Olsson CA, and Benson MC: *Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles*. Urologic Oncology (2004) 22: 107-111.

*Lam JS, Sclar JD, Desai M, Mansukhani M, Benson MC, and **Goluboff ET**: *Is Hispanic race an important predictor of treatment failure following radical prostatectomy for prostate cancer?* J Urol (2004) 172: 1856-1859.

Goetzl MA, Desai M, Mansukhani M, **Goluboff ET**, Katz AE, Sawczuk IS, Benson MC, Olsson CA, and McKiernan JM: *Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult*. Urology (2004) 63: 41-45.

Goetzl MA, **Goluboff ET**, Murphy AM, Katz AE, Mansukhani M, Sawczuk IS, Olsson CA, Benson MC, and McKiernan JM: *A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survival*. Urol Oncol (2004) 22: 182-187.

Murphy AM, Gilbert SM, Katz AE, **Goluboff ET**, Sawczuk IS, Olsson CA, Benson MC, and McKiernan JM: *Re-evaluation of the Tumour-Node-Metastasis staging of locally advanced renal cortical tumours: absolute size (T2) is more significant than renal capsular invasion (T3a)*. BJU Int (2005) 95: 27-30.

Johnson CW, Bingham JB, **Goluboff ET**, and Fisch H: *Transurethral resection of the ejaculatory ducts for treatment of ejaculatory symptoms*. BJU Int (2005) 95: 117-119.

Shabsigh A, Kang Y, Shabsigh R, Gonzalez M, Liberson G, Fisch H, and Goluboff E: *Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism*. J Sexual Medicine (2005) 2: 716-721.

Price D, Stein B, Sieber P, Tutrone R, Bailen J, **Goluboff E**, Burzon D, Bostwick D, and Steiner M: *Toremifene for Prevention of Prostate Cancer in Men with high-grade*

prostatic intra-epithelial neoplasia: Results of double-blind, placebo-controlled, phase IIB clinical trial. J Urol (2006) 176: 965-971.

Gilbert SM, Murphy AM, Katz AE, **Goluboff ET**, Sawczuk IS, Olsson CA, Benson MC, and McKiernan JM: *Reevaluation of TNM staging of renal cortical tumors: Recurrence and survival for T1N0M0 and T3aN0M0 tumors and equivalent.* Urology (2006) 68: 287-291.

Fisch H, Lambert SM, and **Goluboff ET**: *Management of ejaculatory obstruction: Etiology, diagnosis, and treatment.* World Journal of Urology (2006) DOI 10.1007.

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, **Goluboff ET**, and Ennis RD: *Intermediate-risk localized prostate cancer in the PSA era: Radiotherapeutic alternatives.* Urology (2007) 69: 541-546.

*Pierorazio PM, Kinnamon MD, Wosnitzer MS, Benson MC, McKiernan JM, and **Goluboff ET**: *Prostate volume and pathologic prostate cancer outcomes following radical prostatectomy.* Urology (2007) 70: 696-701.

Gjertson CK, Asher KP, Sclar JD, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.* Urology (2007) 70: 723-727.

Capodice JL, Gorroochurn P, Cammack AS, **Goluboff E**, McKiernan JM, Benson MC, Stone BA, and Katz AE: *Zyflamend in men with high-grade prostatic intraepithelial neoplasia: Results of a phase I clinical trial.* JSIO (2009): (In Press).

Sprenkle P, Badalato G, Wosnitzer M, McKiernan J, Parravicini E, Bagiella E, **Goluboff E**, Benson M, and Rutman M: *Exploring medical student education initiatives: Does the management of urologic conditions improve with a formal urology clinical clerkship?* Journal of Medicine and the Person (2011) 9: 116-122.

CASE REPORTS

Goluboff E, O'Toole K, and Sawczuk I: *Leiomyoma of the bladder: Review of the literature.* Urology (1994) 43: 238-241.

Kwan DJ, Kirsch AJ, Chang DT, **Goluboff E**, Berdon WE, and Hensle TW: *Testicular microlithiasis in child with torsion of the appendix testis.* J Urol (1995) 153: 183-184.

Goluboff E, Kaplan SA, and Fisch H: *Seminal vesicle urinary reflux as a complication of transurethral resection of ejaculatory ducts.* J Urol (1995) 153: 1234-1235.

*McKiernan J, Katz A, and **Goluboff E**: *A long forgotten ureteral stent.* Urology (1997) 49: 622-623.

REVIEWS, CHAPTERS, AND EDITORIALS

Goluboff E and Fisch H: *Microsurgical vasovasostomy: Simplified one-layer closure*. Current Surgical Techniques in Urology (1994) 6: 1-7.

Bar-Chama N, **Goluboff E**, and Fisch H: *Pyospermia and male infertility*. Urol Clin North Am (1994) 21: 469-476.

Sawczuk I, **Goluboff E**, and Olsson CA: *Simple Nephrectomy*. in Marshall FF: Operative Urology, 3rd edition 1995.

Goluboff E and Benson M: *Radiation therapy does not provide long-term control of localized prostate cancer*. U Clin NA (1996) 23: 617-621.

Goluboff E, McKiernan JM, and Sawczuk IS: *Autologous T-cell therapy for metastatic renal cell carcinoma*. Today's Therapeutic Trends (1997) 15: 41-51.

Goluboff E (book review, Journal of Urology (1998) 159: 340): *Diagnosis of Genitourinary Disease*, Resnick MI, Older RA, eds., Thieme Medical Publishers, Inc: New York, 1997.

Moss E, Kaplan SA and **Goluboff E**: *Neurogenic bladder*. Hospital Physician, Urology Board Review Manual (1997) 5:1-30.

Moss E and **Goluboff E**: *Superficial bladder cancer*. Hospital Physician, Urology Board Review Manual (1997) 5: 31-60.

Moss E, **Goluboff E** and Chang D: *Cryptorchidism and ureteropelvic junction obstruction*. Hospital Physician, Urology Board Review Manual (1997) 5: 61-90.

Moss E, **Goluboff E** and McKiernan J: *Continent urinary diversion*. Hospital Physician, Urology Board Review Manual (1997) 5: 91-120.

Goluboff E, Fisch H and Hensle T: *Semen analysis and transrectal ultrasound findings in men with bladder exstrophy*. Proceedings of the First International Congress on Bladder Exstrophy, 1997.

Goluboff E, Moss E and Klein L: *Update in male infertility*. Hospital Physician, Urology Board Review Manual (1998) 6(1).

Goluboff E, Moss E and Hendricks J: *Prostate-specific antigen (PSA) and its uses*. Hospital Physician, Urology Board Review Manual (1998) 6(2).

Goluboff E, Moss E and Chang D: *Medical treatment of stone disease*. Hospital Physician, Urology Board Review Manual (1998) 6(3).

Goluboff E, Moss E and Fagelman E: *Interstitial cystitis*. Hospital Physician, Urology Board Review Manual (1998) 6(4).

Hensle TW, **Goluboff E** and Fisch H: *Semen analysis and transrectal ultrasound findings in men with bladder exstrophy*. In: *The Exstrophy-Epispadias Complex*; Gearhart J and Mathews G, eds; Kluwer Academic/Plenum Publishers, New York, p.193-197, 1999.

Chang D, **Goluboff E** and Olsson CA: *The use of a neuromodulator during radical retropubic prostatectomy*. Current Surgical Techniques in Urology (1999) 11: 1-8.

Buttayan R, **Goluboff E** and Olsson CA: *Molecular Biology*. in: Comprehensive Urology; Weiss RM, George NJR, and O'Reilly P, eds; Mosby: Philadelphia, PA, 1999.

Goluboff E, Moss E and Fagelman E: *Diagnosis and treatment of seminoma*. Hospital Physician, Urology Board Review Manual (1999) 7(1).

Goluboff E, Moss E and Stifelman M: *Laparoscopy in urology*. Hospital Physician, Urology Board Review Manual (1999) 7(2).

Goluboff E, Moss E and Taylor J: *Minimally invasive treatments for benign prostatic hyperplasia*. Hospital Physician, Urology Board Review Manual (1999) 7(3).

Goluboff E, Moss E and Fagelman E: *Diagnosis and treatment of vesicoureteral reflux*. Hospital Physician, Urology Board Review Manual (1999) 7(4).

Goluboff E, Klausner A and Zaslau S: Renal cell carcinoma. Hospital Physician, Urology Board Review Manual (2000) 8(1).

Goluboff E, Weiner D and Hensle TW: Hypospadias. Hospital Physician, Urology Board Review Manual (2000) 8(2).

Goluboff E and Hyun G: Impotence. Hospital Physician, Urology Board Review Manual (2000) 8(3).

Goluboff E and Katz A: Natural treatments for prostate cancer. Hospital Physician, Urology Board Review Manual (2000) 8(4).

Goluboff E and Olsson CA: *Radical retropubic prostatectomy*. in: Atlas of Genitourinary Oncology; Movsas B, Olsson C, and Hudes G, eds; W.B. Saunders: Philadelphia, PA, 2001.

Goluboff ET and Fisch H: *Obstruction of the ejaculatory duct system*. In: Pathophysiology and Treatment of Male Sexual and Reproductive Dysfunction, Kandeel F, ed, 2001.

Goluboff ET and Bingham J: *Novel Approaches to treatment of prostate cancer*. Bio Drugs, 2001.

Goluboff ET and Wosnitzer M: *Prostate cancer follow-up*. In: *Cancer Patient Follow-up: An International Perspective*; Johnson F et al, eds; Springer, New York, NY, 2009 (In Press).

ABSTRACTS

Repucci V, **Goluboff E**, Wapner F, and Gouras P: *Retinal pigmented epithelial cell transplantation in the RCS rat*. Invest Ophth (1988), 29(Supp): 144.

Goluboff E, Jarow J, Chang TSK, Zacur H, Schanbacher R, and Marshall FF: *Testicular histology and serum sperm antibodies, inhibin, and FSH levels following vasectomy*. J Urol (1990), 143 (Supp): Abstract #775. (American Urological Association Meeting)

Goluboff E and Olsson CA: *Urologists on a tightrope: Coping with a changing economy*. J Urol (1992), 147(Supp): Abstract #464. (American Urological Association Meeting)

Goluboff E, Mertz JR, Tres LL, and Kierszenbaum AL: *Biochemical, immunocytochemical, and molecular characteristics of human sperm and testis galactosyl receptor*. Fertil Steril (1994), 62: S206. (American Fertility Society Meeting)

Goluboff E, and Fisch H: *Incidence of external spermatic veins in patients undergoing inguinal varicocelectomy*. Fertil Steril (1994), 62: S214. (American Fertility Society Meeting)

Olsson CA, **Goluboff E**, Chang DT, and Kaplan SA: *Urodynamics and the etiology of post-prostatectomy urinary incontinence*. J Urol (1994), 151 (Supp): Abstract #396. (American Urological Association Meeting)

Seaman E, **Goluboff E**, Fisch H: *Accuracy of semen counting chambers as determined by the use of latex beads*. Fertil Steril (1995), 64: S171. (American Fertility Society Meeting)

Fisch H, **Goluboff E**, Olsen JH, Bierbaum R, Diamond B, and Olsson CA: *Semen analyses in 632 men over a 25 year period: No change in quality*. J Urol (1995), 153 (Supp): Abstract #338. (American Urological Association Meeting)

Goluboff E, Hensle TW, and Fisch H: *Semen analysis and transrectal ultrasound findings in men with bladder exstrophy*. J Urol (1995), 153 (Supp): Abstract #29. (American Urological Association Meeting)

Fisch H, **Goluboff E**, Feldshuh J, Seaman E, Barad D, Hendricks J, Olsson CA, Olson J, Bierbaum R, and Broder S: *Semen analyses in 1283 men from the United States over a*

25-year period: No decline in quality. J Urol (1996), 155 (Supp): Abstract #525. (American Urological Association Meeting)

Fisch H, Hendricks J, Klein L, **Goluboff E**, Andrews H, Olson J, and Andrews H: *Sperm counts and birth rates: Do variations correlate?* J Urol (1996), 155 (Supp): Abstract #664. (American Urological Association Meeting)

***Goluboff E**, Shabsigh A, Weinstein IB, Saidi JA, Mitra N, Heitjan DF, Piazza G, Pamukcu R, Buttyan R, and Olsson CA: *Sulindac sulfone (FGN-1) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis.* Society for Basic Urologic Research in association with the 2nd World Congress on Urological Research, 1997. (American Urological Association Meeting)

***Goluboff E**, Heitjan DF, Katz AE and Olsson CA: *Pre-treatment prostate-specific antigen doubling times: Utility in patients before radical prostatectomy.* Program Proceedings of the Annual Meeting of the American Society of Clinical Oncology (1997), 16: 334a, Abstract #1193.

Emanuel ER, **Goluboff E**, and Fisch H: *MacLeod revisited: Sperm count distribution in 374 fertile men from 1971 to 1994.* J Urol (1997), 157 (Supp): Abstract #1451. (American Urological Association Meeting)

Goluboff E, Dorai T, Olsson CA, Katz AE, and Buttyan R: *Anti-bcl-2 ribozyme sensitizes hormone-resistant prostate cancer cells to other therapeutic agents.* J Urol (1997), 157 (Supp): Abstract #21. (American Urological Association Meeting)

Benson MC, **Goluboff E**, and Olsson CA: *Urinary continence after radical retropubic prostatectomy (RRP): Experience at Columbia-Presbyterian Medical Center.* J Urol (1997), 157 (Supp): Abstract #1626. (American Urological Association Meeting)

Shabsigh A, **Goluboff E**, Katz A, Olsson CA, and Buttyan R: *Apoptosis of prostate stromal cells during castration-induced regression of the rat ventral prostate gland.* J Urol (1998), 159 (Supp): Abstract #398. (American Urological Association Meeting)

McKiernan JM, **Goluboff ET**, Olsson CA, Liberson G, Golden R, and Fisch H: *Rising risk of testicular cancer by birth cohort in the United States from 1973-1995.* J Urol (1999), 161 (Supp): Abstract #698. (American Urological Association Meeting)

*Taylor JA, **Goluboff ET**, Holub W, Krane RJ, Fawwaz R, Codington JF, Maimonis P, Lavin PT, and Olsson CA: *The human carcinoma antigen: A new biomarker for prostate cancer.* J Urol (1999), 161 (Supp): Abstract #802. (American Urological Association Meeting)

***Goluboff E**, Olsson C, Prager D, Holden S, Brosman S, Shapiro R, Tchekmedyian S, Gottlieb C, Himsl K, Giantonio B, Rukstalis D, Madorsky M, Barken I, Partin A, Durkin M, Menander K and Pamukcu R: *Exisulind inhibits the progression of prostate cancer in*

men following radical prostatectomy. J Urol (2000) 163: Abstract #705. (American Urological Association Meeting)

Johnson CW, McKiernan JM, Ghafar MA, Anastasiadis AG, **Goluboff ET**, Olsson CA, and Benson MC: *Long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles: Impact of surgical margins.* J Urol (2002) 167: Abstract #909. (American Urological Association Meeting)

***Goluboff E**, Prager D, Rukstalis D, Madorsky M, Holden S, Brosman S, Shapiro R, Tchekmedyian S, Gottlieb C, Himsl K, Weinstein IB, Partin A, and Olsson C: *Long-term use of Exisulind in men with prostate cancer following radical prostatectomy.* J Urol (2002) 167: Abstract #706. (American Urological Association Meeting)

*Lam JS, McKiernan JM, Anastasiadis AG, Benson MC, and **Goluboff ET**: *Comparison of the predictive accuracy of serum PSA levels and PSA Density in the detection of prostate cancer in Caucasian and Hispanic-American Men,* J Urol (2002) 167: Abstract #833. (American Urological Association Meeting)

Kang YM, Cartee TV, Goetzl MA, Katz AE, **Goluboff ET**, Puchner PJ, Olsson CA, McKiernan JM, and Benson MC: *Watchful waiting for prostate cancer reexamined: Intervention free survival while on surveillance in a contemporary cohort of patients.* J Urol (2003) 169, Abstract #1635. (American Urological Association Meeting)

*Lam JS, Desai M, Benson MC, and **Goluboff ET**: *Is Hispanic race an independent risk factor for pathologic stage in patients undergoing radical prostatectomy?* J Urol (2003) 169: Abstract # 1167. (American Urological Association Meeting)

Gondi V, Deutsch I, Vecchio D, **Goluboff E**, and Ennis RD: *Intermediate risk localized prostate cancer: Which radiotherapeutic approach?* J Clin Oncol (2004), Abstract #1101. (Proceedings of the American Society of Clinical Oncology)

Gilbert SM, Murphy AM, Sawczuk IS, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *A re-evaluation of the TNM staging classification of locally advanced renal cortical tumors; Absolute size (T2) is more significant than renal capsular invasion (T3A).* J Urol (2004) 171, Abstract #1776. (American Urological Association Meeting)

Gjertson CK, Asher KP, Sclar JD, Katz AE, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *Local control and long term disease free survival following radical prostatectomy for D1 prostate cancer in the PSA era.* J Urol (2004) 171, Abstract #1461. (American Urological Association Meeting)

Gjertson CK, Kraft KH, Sclar JD, Katz AE, **Goluboff ET**, Olsson CA, McKiernan JM, and Benson MC: *“Heroic” radical prostatectomy: A comparison of actual and predicted disease free survival.* J Urol (2004) 171, Abstract #1056. (American Urological Association Meeting)

Levinson AW, Sclar JD, Kraft KH, Asher KP, Katz AE, Wechsler M, **Goluboff ET**, Benson MC, Olsson CA, and McKiernan JM: *Pathologic findings at cystectomy for bladder cancer: Lack of stage migration over time.* J Urol (2004) 171, Abstract #333. (American Urological Association Meeting)

Goluboff E, Burzon D, Zinner N, Israeli RS, Barnette G, Boger R, Mitchell J and Steiner MS: *Men with high grade prostatic intra-epithelial neoplasia (PIN) remain at high risk for prostate cancer even with a subsequent negative biopsy: Results of a prospective study.* J Clin Oncol (2005), Abstract #365. (Proceedings of the American Society of Clinical Oncology)

Price D, **Goluboff E**, Sieber P, Bostwick D, Barnette KG, and Steiner M: *Toremifine for the prevention of prostate cancer among 514 men with high grade prostatic intraepithelial neoplasia (PIN): Results of a double-blind, placebo-controlled Phase IIB trial.* J Urol (2005) 173, Abstr #690. (American Urological Association Meeting)

Bostwick D, Stein B, Israeli RS, **Goluboff ET**, Barnette KG, and Steiner MS: *Is high-grade prostatic intraepithelial neoplasia (PIN) more frequent than previously estimated?* J Urol (2005) 173, Abstr #1669. (American Urological Association Meeting)

Reese A, Gilbert SM, Katz AE, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *Total number of lymph nodes removed, number of positive nodes, and lymph node density do not correlate with recurrence or survival in node-positive bladder cancer.* J Urol (2005) 173, Abstr #1322. (American Urological Association Meeting)

Hua Y, Gjertson CK, Mitchell RE, Katz AE, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *Can extended lymph node dissection improve biochemical disease free survival following radical retropubic prostatectomy for T1-4N0M0 prostate cancer?* J Urol (2005) 173, Abstr #1027. (American Urological Association Meeting)

Poon SA, Katz MH, Katz AE, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *Does pathologic tumor volume in conventional renal carcinoma predict disease-free survival?* J Urol (2005) 173, Abstr #987. (American Urological Association Meeting)

Kenney PH, Katz MH, Gilbert SM, Katz AE, Samadi D, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *Is partial nephrectomy a feasible option for multiple ipsilateral renal cortical tumors?* J Urol (2005) 173, Abstr #968. (American Urological Association Meeting)

Masson P, Lambert SM, Mitchell R, **Goluboff ET**, Katz AE, Benson MC, Olsson CA, and McKiernan JM: *The predictive value of clinical versus pathological information in prostate cancer: How often is the change significant?* J Urol (2005) 173, Abstr #1496. (American Urological Association Meeting)

Mitchell RE, Shah JB, Desai M, **Goluboff ET**, Katz AE, Petrylak DP, Olsson CA, Benson MC, and McKiernan JM: *Has pre-operative PSA lost the ability to predict*

biochemical failure after radical retropubic prostatectomy? J Urol (2005) 173, Abstr #948. (American Urological Association Meeting)

Mitchell RE, Shah JB, **Goluboff ET**, Katz AE, Olsson CA, Benson MC, and McKiernan JM: *Year of surgery is an independent predictor of biochemical failure following radical prostatectomy for prostate cancer.* J Urol (2005) 173, Abstr #1660. (American Urological Association Meeting)

Murphy AM, Gilbert SM, **Goluboff ET**, Katz AE, Olsson CA, Sawczuk IS, Benson MC, and McKiernan JM: *Re-evaluation of the TNM staging of conventional renal cortical tumors: Outcome of T1N0M0 and T3aN0M0 renal cortical tumors are equivalent.* J Urol (2005) 173, Abstr #988. (American Urological Association Meeting)

Lambert EH, , Pierorazio PM, Poon SA, Katz AE, **Goluboff ET**, Olsson CA, Benson MC, and McKiernan JM: *The increasing use of intravesical therapies for T1 bladder cancer coincides with decreasing survival after cystectomy.* J Urol (2006) 175, Abstr 848. (American Urological Association Meeting)

Sawczuk IS, Munver R, Fromer DL, Volfson IA, Sawczuk A, Galli B, McKiernan JM, **Goluboff ET**, Hoke G, Manetti G, and Benson MC: *Intravesical BCG and interferon alpha 2B therapy prior to cystectomy does not impact negatively on survival in patients with recurrent superficial bladder cancer.* J Urol (2006) 175, Abstr 1255. (American Urological Association Meeting)

*McCann TR, Wosnitzer MS, McKiernan JM, Benson MC, Olsson CA, and **Goluboff ET**: *Risk of disparity between needle biopsy Gleason score and final pathologic Gleason score is not correlated with prostate volume.* J Urol (2006) 175, Abstr 1488. (American Urological Association Meeting)

Mitchell RE, Shah JB, Desai M, Goluboff ET, Katz AE, Olsson CA, Benson MC, and McKiernan JM: *The predictive accuracy of the Gleason system has improved with a trend toward higher grade cancers.* J Urol (2006) 175, Abstr 1586. (American Urological Association Meeting)

King AR, Magai C, Consedine NS, Macchia RJ, Adler HL, McKiernan JM, **Goluboff ET**, Stone BA, Samadi DB, and Neugut AI: *Psychosocial correlates of PSA levels in men attending prostate cancer screening clinics.* Poster presented at the 64th Annual Meeting of the American Psychosomatic Society, Denver, Colorado, March 1-4, 2006.

Levinson AW, Samadi DB, Collins SM, Urdaneta AE, **Goluboff ET**, Benson MC: *Robotic-assisted laparoscopic prostatectomy in obese patients: The Columbia University experience.* J Clin Oncol (2006), Abstract 14619. (Proceedings of the American Society of Clinical Oncology)

Katz AE, Pierorazio PM, Masson P, **Goluboff ET**, Stone BA, McKiernan JM, Benson MC, and Olsson CA: *Results of a Phase I trial administering Zylflamend to subjects with*

high grade prostatic intraepithelial neoplasia. J Clin Oncol (2006), Abstract 14575. (Proceedings of the American Society of Clinical Oncology)

Levinson AW, Berkman DS, **Goluboff ET**, and Samadi DB: *Oncologic significance of pathologic T2 positive surgical margin in robotic-assisted laparoscopic prostatectomy.* J Clin Oncol (2007), Abstract. (Proceedings of the American Society of Clinical Oncology)

*Pierorazio PM, Kinnamon MD, Wosnitzer MS, Benson MC, McKiernan JM, and **Goluboff ET**: *Prostate volume and pathologic prostate cancer outcomes following radical prostatectomy.* J Urol (2007) 177, Abstract 1885. (American Urological Association Meeting)

Akhavan A, Levinson A, Berkman D, Rusnack S, **Goluboff E**, and Samadi D: *Early oncologic outcomes after robotic assisted laparoscopic radical prostatectomy by D'Amico risk stratification.* J Clin Oncol (2008), Abstract 16114. (Proceedings of the American Society of Clinical Oncology)

Berkman D, Akhavan A, Levinson A, Rusnack S, **Goluboff E**, and Samadi D: *Interinstitutional variations in robotic prostatectomy pathologic outcomes for a single surgeon and team.* J Clin Oncol (2008), Abstract 16035. (Proceedings of the American Society of Clinical Oncology)

Samadi D, Akhavan A, Berkman D, Rusnack S, **Goluboff E**, and Levinson A: *Biochemical recurrence after capsular violation during robotic assisted radical prostatectomy.* J Clin Oncol (2008), Abstract 16081. (Proceedings of the American Society of Clinical Oncology)

Kagen AC, Verzosa S, Tareen B, Shasha D, **Goluboff E**, and Ennis RD: *Imaging Treated Prostate Cancer: Appearance on Endorectal MR Imaging after Hormones, Radiation, and Surgery.* Radiology Society of North America (2011).